371 related articles for article (PubMed ID: 26821505)
21. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis.
Özçakar ZB; Özdel S; Yılmaz S; Kurt-Şükür ED; Ekim M; Yalçınkaya F
Clin Rheumatol; 2016 Feb; 35(2):441-6. PubMed ID: 25213327
[TBL] [Abstract][Full Text] [Related]
22. Colchicine failure in familial Mediterranean fever and potential alternatives: embarking on the anakinra trial.
Ben-Zvi I; Livneh A
Isr Med Assoc J; 2014 May; 16(5):271-3. PubMed ID: 24979828
[TBL] [Abstract][Full Text] [Related]
23. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation.
Moser C; Pohl G; Haslinger I; Knapp S; Rowczenio D; Russel T; Lachmann HJ; Lang U; Kovarik J
Nephrol Dial Transplant; 2009 Feb; 24(2):676-8. PubMed ID: 19033248
[TBL] [Abstract][Full Text] [Related]
24. Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment.
Bilgen SA; Kilic L; Akdogan A; Kiraz S; Kalyoncu U; Karadag O; Ertenli I; Dogan I; Calguneri M
J Clin Rheumatol; 2011 Oct; 17(7):358-62. PubMed ID: 21946459
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients.
Başaran Ö; Uncu N; Çelikel BA; Taktak A; Gür G; Cakar N
Mod Rheumatol; 2015 Jul; 25(4):621-4. PubMed ID: 25528863
[TBL] [Abstract][Full Text] [Related]
26. Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare.
Portincasa P
Curr Med Chem; 2016; 23(1):60-86. PubMed ID: 26572612
[TBL] [Abstract][Full Text] [Related]
27. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial.
Hashkes PJ; Spalding SJ; Giannini EH; Huang B; Johnson A; Park G; Barron KS; Weisman MH; Pashinian N; Reiff AO; Samuels J; Wright DA; Kastner DL; Lovell DJ
Ann Intern Med; 2012 Oct; 157(8):533-41. PubMed ID: 23070486
[TBL] [Abstract][Full Text] [Related]
28. Work productivity impairment in patients with familial Mediterranean fever and effects of interleukin-1 antagonists.
Suticen E; Atas N; Guler AA; Akdogan O; Babaoğlu H; Satis H; Karadeniz H; Haznedaroglu S; Ozturk MA; Tufan A
Clin Rheumatol; 2021 Jul; 40(7):2865-2871. PubMed ID: 33527168
[TBL] [Abstract][Full Text] [Related]
29. Familial Mediterranean fever, review of the literature.
Alghamdi M
Clin Rheumatol; 2017 Aug; 36(8):1707-1713. PubMed ID: 28624931
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of anti-interleukin-1 treatment in familial Mediterranean fever patients: a systematic review and meta-analysis.
Kilic B; Guler Y; Azman FN; Bostanci E; Ugurlu S
Rheumatology (Oxford); 2024 Apr; 63(4):925-935. PubMed ID: 37769252
[TBL] [Abstract][Full Text] [Related]
31. Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics.
Grattagliano I; Bonfrate L; Ruggiero V; Scaccianoce G; Palasciano G; Portincasa P
Clin Pharmacol Ther; 2014 Jan; 95(1):89-97. PubMed ID: 23867542
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update.
Cerquaglia C; Diaco M; Nucera G; La Regina M; Montalto M; Manna R
Curr Drug Targets Inflamm Allergy; 2005 Feb; 4(1):117-24. PubMed ID: 15720245
[TBL] [Abstract][Full Text] [Related]
33. Non-response to colchicine in familial Mediterranean fever should be identified accurately.
Melikoglu MA; Senel K
Int J Rheum Dis; 2017 Dec; 20(12):2118-2121. PubMed ID: 24702830
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient.
Seyahi E; Ozdogan H; Masatlioglu S; Yazici H
Clin Exp Rheumatol; 2002; 20(4 Suppl 26):S43-4. PubMed ID: 12371635
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever.
Alpay N; Sumnu A; Calışkan Y; Yazıcı H; Türkmen A; Gül A
Rheumatol Int; 2012 Oct; 32(10):3277-9. PubMed ID: 20386914
[TBL] [Abstract][Full Text] [Related]
36. Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years.
Ben-Chetrit E; Levy M
Semin Arthritis Rheum; 1991 Feb; 20(4):241-6. PubMed ID: 2042056
[TBL] [Abstract][Full Text] [Related]
37. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
Eroglu FK; Beşbaş N; Topaloglu R; Ozen S
Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859
[TBL] [Abstract][Full Text] [Related]
38. [The role of aldosterone and IL-6 in the pathogenesis of inflammation in familial Mediterranean fever].
Dzhndoian ZT; Martirosian NG
Georgian Med News; 2012 May; (206):44-8. PubMed ID: 22870837
[TBL] [Abstract][Full Text] [Related]
39. The clinical role of anakinra in the armamentarium against familial Mediterranean fever.
Parlar K; Ates MB; Egeli BH; Ugurlu S
Expert Rev Clin Immunol; 2024 May; 20(5):441-453. PubMed ID: 38133629
[TBL] [Abstract][Full Text] [Related]
40. Tubular functions in familial Mediterranean fever.
Akkuş S; Calişkan S; Kasapçopur O
Turk J Pediatr; 2002; 44(4):317-20. PubMed ID: 12458807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
